BiOneCure Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for BIO-106, an antibody-drug conjugate (ADC) designed to target TROP-2 to treat a broad range of advanced solid tumors.
| GERMANTOWN, Md., April 6, 2022 /PRNewswire/ -- BiOneCure Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for BIO-106, an antibody-drug conjugate (ADC) designed to target TROP-2 to treat a broad range of advanced solid tumors.
This IND approval is a significant milestone for both our team and the patients we hope to serve. The clinical study cleared by the FDA, known as StarBridge-1, is a Phase I/II, multicenter, open-label study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of BIO-106 as monotherapy and in combination with pembrolizumab in patients with advanced cancers “This is the first IND approval for BiOneCure. It is a significant milestone for both our team and the patients we hope to serve.” said Haifeng Bao, Ph.D., Co-founder and Chief Executive Officer at BiOneCure. “BiOneCure has complete intellectual property rights of the product, covering the payload, antibody and the ADC drug product, The introduction of our innovatively developed ADC candidate BIO-106 validated our approach to the next generation of ADC. We are very excited to bring the new molecule to the clinical stage and look forward to advancing this trial” About BIO-106 About BiOneCure Therapeutics BioOneCure Contacts:
SOURCE BiOneCure |
View original content to download multimedia:
